Pacientes infectados pelo HIV apresentam resposta de imunogenicidade menor àquela obtida pela população geral com a imunização de rotina. A vacina meningocócica C conjugada é indicada para essa população, não existindo pesquisas prévias que avaliassem a imunogenicidade desta, para esse grupo específico. O estudo realizou essa avaliação comparando a resposta vacinal entre os pacientes infectados e não infectados pelo HIV, as relações dessa resposta com parâmetros clínicos e laboratoriais da infecção pelo vírus e os eventos adversos à vacinação. Utilizou-se as técnicas ensaios de anticorpos bactericidas séricos ou ação bactericida no soro (SBA) e o enzyme-linked immunosorbent assay (ELISA). Tratou-se de um ensaio clínico, envolvendo 92 pacientes, com idades entre 10-20 anos, sendo 43 infectados e 49 não infectados pelo HIV. Após a vacinação, 72,1% do grupo HIV+ e 100% do grupo HIV- foram considerados protegidos. Os pacientes do grupo HIV+ não respondedores à vacinação foram revacinados, tendo sido respondedores a essa nova dose 40% destes. Portanto, 81,4% dos pacientes infectados pelo HIV adquiriram proteção com a vacina (após uma ou duas doses). Foi encontrada correlação da resposta vacinal com o número de esquemas antirretrovirais previamente utilizados e carga viral pré-vacinação, não havendo outras associações com os demais parâmetros clínicos e laboratoriais da infecção pelo HIV. Pacientes com adequada resposta vacinal tenderam a ser os de menor idade. Efeitos colaterais ocorreram em 16,3% no grupo HIV+ e em 44% no HIV-. Conclui-se que a vacina meningocócica C conjugada é segura e efetiva para uso em adolescentes e adultos jovens com aids, embora a resposta de anticorpos seja menor do que a observada em indivíduos saudáveis. Isso indica a necessidade de discussão de novos esquemas de imunização em infectados pelo HIV, objetivando uma proteção mais efetiva contra doença meningocócica / Children and adolescents infected with HIV typically have a weaker response to immunization in comparison with the healthy population. The meningococcal C conjugate vaccine is routinely recommended for those individuals. No studies, however, have evaluated the antibody response to this vaccine in HIV-infected patients yet. In this study, we compared the antibody response to the meningococcal C conjugate vaccine between HIV-infected and HIV-uninfected patients using the serum bactericidal antibody assay (SBA) and the enzyme-linked immunoabsorbent assay (ELISA). Additional objectives were to determine whether the acquired immunity correlated with clinical and laboratory features of HIV infection, and to evaluate the vaccine side effects in this population. This clinical trial included 92 patients aged 10 to 20 years old: 43 HIV-infected and 49 HIV-uninfected patients. After one single dose of the vaccine, 72.1% of the HIV-infected and 100% of the HIV-uninfected patients were considered protected. Of the HIV-infected patients (non-responders in first dose) who received a second dose of the vaccine, only 40% reached protective antibody levels. Overall, 81.4% of the HIV-infected patients reached protective antibody titres (after one or two doses of the vaccine). The antibody response in HIV-infected patients correlated with the number of prior antiretroviral therapy schedules and with the pre-vaccination viral load, but with no other clinical features or laboratory tests. Patients with adequate vaccinal response tended to be younger. Side effects occurred in 16.3% and 44% of the HIV-infected and HIV-uninfected groups, respectively. In conclusion, the meningococcal serogroup C conjugate vaccine proved to be safe and effective in HIV-infected adolescents and young adults, although their antibody response was weaker than that of HIV-uninfected patients. These results suggest that the immunization schedule for HIV-infected patients should be re-evaluated, in order to assure more effective protection against the meningococcal disease in this population

INTRODUÇÃO: A propensão do CaP em gerar metástases decorre de mecanismos moleculares específicos em um processo composto por múltiplas etapas, sendo que o remodelamento do meio extracelular através de ações de enzimas proteolíticas denominadas metaloproteinases da matriz (MMP) é uma etapa fundamental. As MMP degradam vários componentes da matriz extracelular, sendo que seu controle pode ser exercido por outras proteínas denominadas TIMPs. Em nível gênico, outro controle pode ser exercido por moléculas chamadas microRNAs. OBJETIVO: O objetivo deste estudo é avaliar a regulação da MMP-9 por miRNAs. A partir de dados da literatura identificamos que a MMP-9 pode sofrer influência do miR-21 e 338-3p. MÉTODOS: Para os experimentos in vitro, linhagens celulares de CaP (DU145, PC3 e LNCaP) foram transfectadas com os miRNAs de interesse e a expressão de MMP-9 foi avaliada por reação em cadeia de polimerase quantitativa com transcriptase reversa (qRT-PCR). O sobrenadante da transfecção foi usado para ensaios de invasão com matrigel, e ELISA. Nos experimentos in vivo, células da linhagem PC-3-luc foram implantadas no subcutâneo de camundongos Balb-c nude e tratadas com injeções de anti-miR-21, miR-338-3p ou a combinação de ambos. RESULTADOS: O miR-21 aumentou expressão de MMP-9 em 72% na PC3. Houve maior invasão celular tanto na PC3 como DU145. In vivo, o bloqueio do miR-21 reduziu em 10% a expressão de MMP-9 nos tumores implantados (p=0,04). O miR-338-3p reduziu a expressão de MMP-9 em 53% na PC3 (p=0,001), 31% na LnCaP (p=0,23) e 24% na DU145 (p=0,16). No ensaio de invasão, menor número de células e colônias foram capazes de invadir a membrana de matrigel. In vivo, houve redução de 27% na expressão de MMP-9 nos camundongos tratados com o miR-338-3p (p=0,07). A combinação anti-miR-21+miR-338-3p reduz a expressão de MMP-9 em maior intensidade tanto in vitro como in vivo. CONCLUSÕES: A expressão de MMP-9 pode ser regulada pelo miR-21 e miR-338-3p. O primeiro se comporta como um oncomiR ao passo que o segundo como um supressor tumoral. A combinação de miRNAs é uma estratégia plausível para ampliar o efeito sobre expressão de genes de interesse / INTRODUCTION: The propensity of CaP to generate metastases results from specific molecular mechanisms in a multiphase process and the remodeling of the extracellular medium through the actions of proteolytic enzymes called matrix metalloproteinases (MMP) is a fundamental step. MMPs degrade several components of the extracellular matrix, and their control can be exerted by other proteins called TIMPs. At the gene level, another control can be exerted by molecules called microRNAs. OBJECTIVE: The objective of this study is to evaluate the regulation of MMP-9 by miRNAs. From literature data we have identified that MMP-9 may be influenced by miR-21 and 338-3p. METHODS: For in vitro experiments, CaP cell lines (DU145, PC3 and LNCaP) were transfected with the miRNAs of interest and the expression of MMP-9 was assessed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). The transfection supernatant was used for matrigel and ELISA invasion assays. For the in vivo experiments, PC3-luc cells were implanted into the subcutaneous Balb-c nude mice and treated with anti-miR-21, miR-338-3p injections or the combination of both. RESULTS: The miR-21 increased MMP-9 expression by 72% in PC3. There was greater cell invasion in both PC3 and DU145. In vivo, miR-21 blockade reduced MMP-9 expression by 10% in implanted tumors (p = 0.04). MiR-338-3p reduced MMP-9 expression by 53% in PC3 (p = 0.001), 31% in LNCaP (p = 0.23), and 24% in DU145 (p = 0.16). In the invasion assay, fewer cells and colonies were able to invade the matrigel membrane. In vivo, there was a 27% reduction in MMP-9 expression in mice treated with miR-338-3p (p = 0.07). The combination of anti-miR-21 + miR-338-3p reduces MMP-9 expression in greater intensity both in vitro and in vivo. CONCLUSIONS: MMP-9 expression can be regulated by miR-21 and miR-338-3p. The former behaves as an oncomyR while the second as a tumor suppressor. The combination of miRNAs is a plausible strategy to extend the effect on gene expression of interest

No description available.

Cloninger’s Psychobiological Theory of Personality proposes four temperament dimensions, each underpinned by a different neurotransmitter system. The serotonergic system is purportedly linked to Harm Avoidance (HA). The aim of this study was to explore the relationship between HA and serotonin in migraine without aura (MO). A second aim was to explore the personality profile of MO patients. Sixty-six participants completed an online questionnaire and donated blood samples. Results indicated no significant association between HA and serotonin and a significant relationship between MO and HA. This study indicates that both Cloninger’s Psychobiological Theory of Personality and the Tridimensional Personality Questionnaire used for its assessment have value in South African personality research. In addition, the findings of the study reveal support for personality influences on the processes involved in migraine. This not only produces worthwhile avenues of research but also an alternative perspective for clinical practice. / Psychology / M.A. (Psychology (Research Consultation))

O objetivo deste estudo foi avaliar a contribuição de linfoproliferação (1 parâmetro) em associação a provas sorológicas de alto desempenho (4 parâmetros), estudo epidemiológico (1) e parasitológico (1) em indivíduos com sorologia convencional inconclusiva para a doença de Chagas. Mostramos que o diagnóstico de doença de Chagas é provável quando 3 ou mais desses parâmetros são positivos em 7 (15/73). A combinação: TESA-blot e linfoproliferação positivos revelou-se útil diante de antecedentes epidemiológicos positivos / This study aims to evaluate the contribution of lymphoproliferation (1 parameter) in association with high performance serological tests (4), epidemiological data (1) and parasitological tests (1) for Chagas disease in patients with inconclusive conventional serological tests. We showed that this diagnosis is probable in individuals presenting > three positive of these 7 parameters (15 of 73 individuals). The combination of TESA-blot, lymphoproliferation was useful when epidemiological data were positive

Neste estudo avaliamos a resposta imune humoral de indivíduos naturalmente expostos à malária em áreas endêmicas no Brasil. Os anticorpos IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgE e IgA anti-formas eritrocitárias de Plasmodium falciparum foram determinadas por ELISA. Anticorpos IgG, IgG1, IgG2 de alta avidez e IgG3 de baixa avidez predominaram nos indivíduos sem complicações de malária ou assintomáticos, enquanto anticorpos IgG4, IgE e IgM predominaram nos indivíduos com complicações clínicas por malária. Os resultados mostram que mesmo em regiões com transmissão instável de malária pode ser observado o desenvolvimento de imunidade protetora quando anticorpos apropriados são produzidos / In this study, we have evaluated the humoral immune response of individuals naturally exposed to malaria living in endemic areas of Brazil. We determined IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgE and IgA antibodies against Plasmodium falciparum blood stages by ELISA. We observed that the level of high avidity IgG, IgG1 and IgG2 and low avidity IgG3 antibodies were higher in asymptomatic individuals or with uncomplicated malaria, while IgG4, IgE and IgM antibodies were higher in individuals with complicated malaria. Taken together the results showed that even in unstable malaria regions it can be observed the development of protective immunity against malaria when appropriate antibodies are produced

Abstract Endometrial carcinoma is the most common gynegologic malignancy in developed countries. Due to early symptoms, including abnormal uterine bleeding, endometrial cancer is often diagnosed at an early stage and in that case usually has a good prognosis and high cure rates. However, the nature of the disease is heterogeneous. During the last decades, the improvement in survival rates among endometrial cancer patients has not been significant, suggesting that the traditional clinicopathological factors may be inadequate to identify patients with high-risk disease. Furthermore, aggressive adjuvant treatments can be costly and very toxic. Therefore, better prognostic markers associated with biological aggressiveness of endometrial carcinoma are needed to identify the patients with high-risk disease, and to be able to select the treatment more individually. Gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) have been found to play a role in tumor progression. In the present work, the expression and prognostic value of MMP-2, MMP-9, TIMP-1 and TIMP-2 were assessed in endometrial carcinoma. The patient material consisted of a total of 266 women diagnosed with primary endometrial carcinoma. The tissue expression of immunoreactive proteins was examined in paraffin-embedded tumor sections by immunohistochemical staining using specific antibodies, and the pretreatment serum levels of the proteins were quantitatively measured by ELISA. Tissue MMP-2 expression associated with a worsened prognosis, whereas tissue TIMP-2 overexpression was an indicator of a favorable outcome. Furthermore, we observed a combination of strong MMP-2 and weak TIMP-2 tissue expression to identify a group of women at high risk of adverse outcome in endometrial carcinoma. Patients with negative MMP-2 immunostaining had the best prognosis, regardless of TIMP-2 staining result. In serum measurements, high preoperative TIMP-1 concentration was a prognostic indicator of unfavorable outcome. These results indicate that tissue MMP-2 and TIMP-2 as well as circulating TIMP-1 may be prognostic markers in endometrial carcinoma. Of these, tissue MMP-2 seems to be the most potent prognostic marker. Studies with larger patient materials are needed to further explore the value of these enzymes in clinical practice in endometrial cancer. / Tiivistelmä Kohdunrungon syöpä on yleisin gynekologinen maligniteetti kehittyneissä maissa. Varhaisten oireiden, kuten poikkeavan verisen vuodon, vuoksi kohdunrungon syöpä havaitaan usein varhaisessa vaiheessa, jolloin sen ennuste on hyvä. Taudin käyttäytyminen voi kuitenkin olla moninaista. Viime vuosikymmenten aikana kohdunrungon syöpään sairastuneiden ennuste ei ole merkittävästi parantunut. Vaikuttaisi siltä, että perinteiset ennustetekijät eivät ole riittävän tarkkoja ennustamaan syövän taudinkulkua. Lisäksi liitännäishoidot voivat olla kalliita, ja niihin voi liittyä vakavia haittavaikutuksia. Uusien biologisten ennustetekijöiden löytäminen olisi tärkeää, jotta aggressiivista syöpätyyppiä sairastavat potilaat pystyttäisiin tunnistamaan entistä paremmin, ja hoito kyettäisiin räätälöimään yksilöllisemmin taudinkuvaa vastaavasti. Gelatinaasien (MMP-2 ja MMP-9) sekä niiden kudosinhibiittoreiden (TIMP-1 ja TIMP-2) on havaittu osallistuvan syövän etenemiseen. Tässä tutkimuksessa tarkasteltiin MMP-2:n ja MMP-9:n sekä niiden kudosinhibiittoreiden TIMP-1:n ja TIMP-2:n ilmentymistä ja ennusteellista merkitystä kohdunrungon syövässä. Aineisto käsitti yhteensä 266 primaariseen kohdunrungon syöpään sairastunutta naista. Määritysmenetelminä käytettiin sekä immunohistokemiallista värjäystä parafiiniin valettujen kudosnäytteiden osalta että ELISA-määrityksiä ennen hoitoa otettujen seeruminäytteiden osalta. Syöpäkudoksen runsas MMP-2 -proteiinin ilmentyminen liittyi epäsuotuisaan ennusteeseen, kun taas kasvainkudoksen voimakas TIMP-2 -proteiinin ilmentyminen oli hyvän ennusteen merkki. Lisäksi kasvainkudoksen voimakkaan MMP-2- ja heikon TIMP-2 -proteiinien ilmentymisen yhdistelmän havaittiin liittyvän suurempaan syövästä johtuvaan kuolleisuuteen. MMP-2 -negatiivisten potilaiden eloonjäämisennuste oli paras, TIMP-2 -värjäystuloksesta riippumatta. Seerumin korkea TIMP-1 -pitoisuus oli merkittävä huonontuneen ennusteen merkki. Tutkimuksen tulokset viittaavat siihen, että kasvainkudoksessa esiintyvät MMP-2- ja TIMP-2 -proteiinit samoin kuin seerumin TIMP-1 -pitoisuus voivat ennustaa kohdunrungon syövän kliinistä käyttäytymistä. Kasvainkudoksessa esiintyvä MMP-2 -proteiini vaikuttaisi olevan merkittävin ennusteellinen tekijä, mutta tulosten varmistamiseksi tarvitaan lisää tutkimuksia suuremmilla potilasaineistoilla.

Along with proteins, a myriad of different molecular biomarkers, such as post-translational modifications and autoantibodies, could be used in an attempt to improve disease detection and progression. In this thesis, I build on several iterations of the proximity ligation assay to develop and apply new adaptable methods to facilitate detection of proteins, autoantibodies and post-translational modifications. In paper I, we present an adaptation of the solid-phase proximity ligation assay (SP-PLA) for the detection of post-translational modification of proteins (PTMs). The assay was adapted for the detection of two of the most commons PTMs present in proteins, glycosylation and phosphorylation, offering the encouraging prospect of using detection of PTMs in a diagnostic or prognostic capacity.  In paper II, we developed a variant of the proximity ligation assay using micro titer plate for detection and quantification of protein using optical density as readout in the fluorometer, termed PLARCA. With a detection limit considerably lower than ELISA, PLARCA detected femtomolar levels of these proteins in patient samples. In paper III, we aim to compare detection values of samples collected from earlobe capillary, venous plasma, as well as capillary plasma stored in dried plasma spots (DPS) assessed with a 92-plex inflammation panel using multiplex proximity extension assay (PEA). Despite the high variability in protein measurements between the three sample sources, we were able to conclude that earlobe capillary sampling is a suitable less invasive alternative, to venipuncture. In paper IV, we describe the application of PLARCA and proximity extension assay (PEA) for the detection of GAD65 autoantibodies (GADA). Thus, offering highly sensitive and specific autoimmunity detection.

Cardiovascular diseases are a broad group of diseases, such as heart attack and heart failureaffecting the cardiovascular system. The primary cause of cardiovascular diseases isatherosclerosis, and its progression is brought about by oxidative stress and a complex chronicinflammation reaction cascade. Of central importance are proinflammatory cytokines, regulatedby multiple factors, including interleukin (IL) 17A. This project aims to investigate the effectof IL-17A on the inflammatory response of human vascular endothelial cells by quantifyingchemokine C-X-C motif ligand-1 (CXCL1) release when exposed or not to otherproinflammatory mediators such as TNF-𝛼, IL-6 and IL-1β. To investigate this, humanumbilical cord endothelial cells were cultured and then stimulated with IL-17A alone or incombination with other cytokines, namely IL-6/sIL6R, IL-1β, or TNF-𝛼. After an appropriateincubation time following the stimulations, the supernatants of the cells were collected, and theamount of CXCL1 was analysed with ELISA or qPCR, respectively. At a lower concentration(10ng/ml), IL-17A failed to induce a significant level of CXCL1 release from endothelial cells.However, IL-17A + TNF-𝛼 (5ng/ml) greatly enhanced, higher than inductions from individualtreatments combined, level of CXCL1 release from endothelial cells. Furthermore, combiningIL-17A with IL-1β or IL-6 induced non-abundant and abundant upregulation in CXCL1 release,respectively. On transcription level, the amount of CXCL1 mRNA induced by IL-17A alonewas non-significant, but stimulation with TNF-𝛼 and IL-17A + TNF-𝛼 induced significantlyupregulated expression of CXCL1. In conclusion, we found that IL-17A induced synergeticrelease of CXCL1 in human vascular endothelial cells with TNF-𝛼. In addition, the synergisticimpact of IL-17A and TNF-𝛼 in terms of CXCL1 induction in vascular endothelial cells wasevident on a transcriptional level. Our data imply that combined blockage of IL-17A and TNF-𝛼 could have an enhanced therapeutic effect on vascular inflammation.

BACKGROUND: Numerous studies have suggested that Helicobacter pylori infection in asymptomatic subjects is transmitted from person to person. Its prevalence is higher in the institutionalized setting. If that is the case, persons involved in patient care should have a higher prevalence of the infection. METHODS: We estimated the prevalence of H pylori antibodies among groups of asymptomatic medical and nursing staff and compared them with volunteer blood donors of similar age and sex. RESULTS: One hundred fifty-eight nurses and aides, 59 residents, 46 senior medical students, and 22 senior nursing students were enrolled in this study. Serum samples were tested for IgG antibodies against H pylori by enzyme-linked immunosorbent assay. Sixty-two (39%) of 158 nurses were found to be positive for antibodies to H pylori compared with 114 (26%) of 441 specimens from the blood donor group. Within the youngest age group (20 to 34 years), 13 (25%) of 51 nurses were positive for H pylori antibodies compared with 19 (13%) of 143 age-matched serum samples from the blood donor group. Within the middle age group (35 to 49 years), 32 (39%) of 83 nurses were positive for H pylori antibodies vs 43 (26%) of 167 age-matched blood donors. In the oldest age group (> 50 years), 17 (71%) of 24 nurses were positive for H pylori antibodies compared with 52 (40%) of 131 age-matched blood donors. Twenty-three (27%) of 86 nurses with 1 to 15 years of occupational exposure were positive for H pylori antibodies compared with 40 (56%) of 72 nurses with more than 15 years of occupational exposure. CONCLUSIONS: Nurses have an increased prevalence of H pylori antibodies that is significantly higher than the comparable prevalence of volunteer blood donors and is evident in the youngest age group. In addition, the increased prevalence is related to a longer duration of patient exposure in the nursing group.